Glassman Wealth Services Sage Therapeutics, Inc. Transaction History

Glassman Wealth Services

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$17.1 - $22.26 $1,077 - $1,402	-63 Reduced 81.82%	14 $0
Q3 2023 Nov 13, 2023	BUY	$16.75 - $48.98 $1,289 - $3,771	77 New	77 $1,000
Q1 2022 Apr 14, 2022	SELL	$30.71 - $45.71 $9,243 - $13,758	-301 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$37.06 - $47.11 $9,339 - $11,871	252 Added 514.29%	301 $13,000
Q3 2021 Nov 10, 2021	SELL	$40.26 - $57.37 $3,140 - $4,474	-78 Reduced 61.42%	49 $2,000

Q2 2021 Aug 04, 2021	BUY	$54.88 - $79.29 $109 - $158	2 Added 1.6%	127 $7,000
Q4 2020 Feb 04, 2021	BUY	$58.41 - $89.06 $4,672 - $7,124	80 Added 177.78%	125 $11,000
Q2 2020 Aug 06, 2020	BUY	$25.95 - $43.15 $570 - $949	22 Added 95.65%	45 $2,000
Q1 2020 May 12, 2020	BUY	$26.15 - $77.24 $523 - $1,544	20 Added 666.67%	23 $1,000
Q4 2019 Feb 07, 2020	BUY	$60.18 - $154.77 $180 - $464	3 New	3 $0
Q3 2019 Nov 01, 2019	SELL	$140.29 - $189.96 $1,262 - $1,709	-9 Closed	0 $0
Q2 2019 Aug 08, 2019	BUY	$157.85 - $183.09 $1,420 - $1,647	9 New	9 $2,000

222

52.7M

207K

191K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $641M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Glassman Wealth Services, based on Form 13F filings with the SEC.

Stay updated on Glassman Wealth Services with notifications on news.